Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex

被引:463
作者
Staker, BL
Feese, MD
Cushman, M
Pommier, Y
Zembower, D
Stewart, L
Burgin, AB
机构
[1] DeCODE BioStruct, Bainbridge Isl, WA 98110 USA
[2] Purdue Univ, Sch Pharm & Pharmaceut Sci, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA
[3] NCI, Mol Pharmacol Lab, Div Basic Sci, Bethesda, MD 20892 USA
关键词
D O I
10.1021/jm049146p
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Human topoisomerase I (top1) is the molecular target of a diverse set of anticancer compounds, including the camptothecins, indolocarbazoles, and indenoisoquinolines. These compounds bind to a transient top1-DNA covalent complex and inhibit the resealing of a single-strand nick that the enzyme creates to relieve superhelical tension in duplex DNA. (Hertzberg, R. P.; et al. Biochem. 1989,28, 4629-4638. Hsiang, Y. H.; et al. J. Biol. Chem 1985,260,14873-14878. Champoux, J. J. Annu. Rev. Biochem. 2001, 70, 369-413. Stewart, L.; et al. Science 1998, 729, 1534-1541.) We report the X-ray crystal structures of the human top1-DNA complex bound with camptothecin and representative members of the indenoisoquinoline and indolocarbazole classes of top1 poisons. The planar nature of all three structurally diverse classes allows them to intercalate between DNA base pairs at the site of single-strand cleavage. All three classes of compounds have a free electron pair near Arg364, a residue that if mutated confers resistance to all three classes of drugs. The common intercalative binding mode is augmented by unexpected chemotype-specific contacts with amino acid residues Asn352 and Glu356, which adopt alternative side-chain conformations to accommodate the bound compounds. These new X-ray structures explain how very different molecules can stabilize top1-DNA covalent complexes and will aid the rational design of completely novel structural classes of anticancer drugs.
引用
收藏
页码:2336 / 2345
页数:10
相关论文
共 60 条
[1]   CHARACTERIZATION OF A MAMMALIAN MUTANT WITH A CAMPTOTHECIN-RESISTANT DNA TOPOISOMERASE-I [J].
ANDOH, T ;
ISHII, K ;
SUZUKI, Y ;
IKEGAMI, Y ;
KUSUNOKI, Y ;
TAKEMOTO, Y ;
OKADA, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (16) :5565-5569
[2]  
ANTONY S, 2003, CANCER RES, P63
[3]   Homocamptothecins: potent topoisomerase I inhibitors and promising anticancer drugs [J].
Bailly, C .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2003, 45 (01) :91-108
[4]   The camptothecin-resistant topoisomerase I mutant F361S is cross-resistant to antitumor rebeccamycin derivatives. A model for topoisomerase I inhibition by indolocarbazoles [J].
Bailly, C ;
Carrasco, C ;
Hamy, F ;
Vezin, H ;
Prudhomme, M ;
Saleem, A ;
Rubin, E .
BIOCHEMISTRY, 1999, 38 (27) :8605-8611
[5]   DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin [J].
Bailly, C ;
Riou, JF ;
Colson, P ;
Houssier, C ;
RodriguesPereira, E ;
Prudhomme, M .
BIOCHEMISTRY, 1997, 36 (13) :3917-3929
[6]  
BENEDETTI P, 1993, CANCER RES, V53, P4343
[7]  
BJORNSTI MA, 1989, CANCER RES, V49, P6318
[8]  
Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254
[9]   A NOVEL SUICIDE SUBSTRATE FOR DNA TOPOISOMERASES AND SITE-SPECIFIC RECOMBINASES [J].
BURGIN, AB ;
HUIZENGA, BN ;
NASH, HA .
NUCLEIC ACIDS RESEARCH, 1995, 23 (15) :2973-2979
[10]   DNA topoisomerases: Structure, function, and mechanism [J].
Champoux, JJ .
ANNUAL REVIEW OF BIOCHEMISTRY, 2001, 70 :369-413